Genix Pharmaceuticals Cash Flow Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	2020 - 2016
Net Income	-0.34	-0.07	-4.4	-1.07	-1.65	Upgrade
Depreciation & Amortization	-	-	0.55	0.56	0.54	Upgrade
Other Amortization	0	0	0	0	0	Upgrade
Asset Writedown & Restructuring Costs	0.01	-	3.46	-	-	Upgrade
Stock-Based Compensation	-	0.03	0.06	0.26	0.81	Upgrade
Other Operating Activities	0.17	-0.17	0.06	0.04	0	Upgrade
Change in Accounts Receivable	0	-0	0.02	-0.01	0	Upgrade
Change in Inventory	-	-0	0.01	-0.17	-0	Upgrade
Change in Accounts Payable	0.01	0.04	0.03	0.18	-0.09	Upgrade
Change in Other Net Operating Assets	0.02	-0	-0	-0	-0.03	Upgrade
Operating Cash Flow	-0.12	-0.19	-0.22	-0.22	-0.43	Upgrade
Sale (Purchase) of Intangibles	-	-	-	-0	-	Upgrade
Investing Cash Flow	-	-	-	-0	-	Upgrade
Short-Term Debt Issued	0.09	0.19	0.28	0.17	-	Upgrade
Total Debt Issued	0.09	0.19	0.28	0.17	-	Upgrade
Long-Term Debt Repaid	-0.03	-	-	-0.02	-0.01	Upgrade
Total Debt Repaid	-0.03	-	-	-0.02	-0.01	Upgrade
Net Debt Issued (Repaid)	0.06	0.19	0.28	0.15	-0.01	Upgrade
Issuance of Common Stock	0.1	-	-	-	-	Upgrade
Other Financing Activities	-0	-	-0.06	-0.05	-0.12	Upgrade
Financing Cash Flow	0.16	0.19	0.22	0.09	-0.13	Upgrade
Net Cash Flow	0.03	-0	0	-0.13	-0.56	Upgrade
Free Cash Flow	-0.12	-0.19	-0.22	-0.22	-0.43	Upgrade
Free Cash Flow Margin	-	-4624.54%	-1787.27%	-	-	Upgrade
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-0.00	-0.01	Upgrade
Cash Interest Paid	-	-	-	0	-	Upgrade
Levered Free Cash Flow	-0.15	-0.53	0.06	0.17	0.68	Upgrade
Unlevered Free Cash Flow	-0.04	-0.46	0.09	0.18	0.68	Upgrade
Change in Working Capital	0.03	0.03	0.06	-0.01	-0.12	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.